Sam Edland is a senior manager in the life sciences business advisory practice at Wilson Sonsini Goodrich & Rosati. Based in Boston, his practice focuses on advising early-stage life sciences companies on transactional initiatives with valuations, business insights, capabilities, and strategies to help them thrive and address some of their most challenging issues.

Sam has held roles of increasing responsibility across a diverse range of private and public biopharma, diagnostics, and healthcare enterprises ranging from three-person seed-stage start-ups to Fortune 6 companies, in addition to working in seed-stage venture capital.

Prior to joining Wilson Sonsini, Sam was at Biogen on the business development and M&A team. Before that, he spent time at Foundation Medicine in corporate development (acquired by Roche Pharmaceutical), and in corporate strategy and new ventures at The Advisory Board Company (acquired by UnitedHealthGroup). Additionally, he has been working in parallel as a due diligence consultant and Investment Review Committee member of Ben Franklin Technology Partners, an impact investment fund based in Philadelphia, since 2017.

During his undergraduate studies, he spent his collective summers and winters at The National Institutes of Health. During his graduate studies, he served as an independent consultant to several healthcare start-ups, in addition to serving as a research assistant in The Office of Andrew P. Miller, Former Attorney General of Virginia, where he focused on lobbying at the state level.